Investor Area

Array
(
    [0] => https:
    [1] => 
    [2] => www.clinuvel.com
    [3] => investors
    [4] => news
)
Home / Investors / News

News

04 April 2019   Download PDF to view presentation

Download PDF
 

Melbourne, Australia and Leatherhead, UK, 29 March 2019 Download PDF to read more CLINUVEL PHARMACEUTICALS LTD today announced that it will host national expert meetings in Berlin, Germany, on 29 March and Florence, Italy, on 5 April to evaluate the treatment of erythropoietic protoporphyria (EPP). Clinicians and medical staff from a number of EPP expert […]

Download PDF
 
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019 Download PDF   Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead.   FDA REVIEW At the time of print CLINUVEL will find itself within four months of the US Prescription Drug User Fee Act (PDUFA) date, while […]

Download PDF
 
Friday, 15 March 2019

UK NICE Meeting Held

Melbourne, Australia, 15 March 2019 Third meeting of Highly Specialised Technology Committee CLINUVEL PHARMACEUTICALS LTD  announced that it had met with the Highly Specialised Technology (HST) Committee of the English National Institute of Health and Care Excellence (NICE) in Manchester on 14 March (Greenwich Mean Time) as part of the ongoing evaluation of CLINUVEL’s drug […]

Download PDF
 
Wednesday, 13 March 2019

Change in substantial holding

13 March 2019   Form 604Corporations Act 2001Section 671BNotice of change of interests of substantial holder   Download PDF to read more

Download PDF
 
Wednesday, 13 March 2019

Change in substantial holding

13 March 2019   Form 604Corporations Act 2001Section 671BNotice of change of interests of substantial holder   Download PDF to read more

Download PDF
 

13 March 2019   Change of Director’s Interest Notice   Download PDF to read more

Download PDF
 
Wednesday, 13 March 2019

Appendix 3B

13 March 2019   New issue announcement, application for quotation of additional securities and agreement   Download PDF to read more

Download PDF
 
Monday, 04 March 2019

Investor Briefing

4 March 2019 Investor Briefing – Non-Deal Roadshow Download PDF to read more

Download PDF
 
Tuesday, 26 February 2019

Appendix 4D Half Yearly Report

Melbourne, Australia, 26 February 2019 CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4D – Half Yearly Report for the period 01 July to 31 December 2018. All figures are rounded and reported in Australian […]

Download PDF
 
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. Although it is widely accepted in photodermatology that NB-UVB is not a reliable and effective therapy for vitiligo, […]

Download PDF
 
Thursday, 07 February 2019

CLINUVEL Newsletter – February 2019

7 February 2019 Dear patients, shareholders, friends, In this second Communiqué for the year we will delve deeper in the ongoing treatment of erythropoietic protoporphyria (EPP) patients in Europe and look ahead at the expected news flow from the US Food and Drug Administration (FDA) in the coming months. Gradually, we are sharing the contours […]

Download PDF
 
Thursday, 31 January 2019

Appendix 4C

31 January 2019   Melbourne, Australia and Leatherhead, UK   CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 October to 31 December 2018. All figures are […]

Download PDF
 
Tuesday, 29 January 2019

Change of Director’s Interest Notice

Melbourne, Australia 29 January 2019 The following Appendix 3Y Change of Director’s Interest Notice relates to a notifiable interest in CLINUVEL PHARMACEUTICALS LTD for Mrs Brenda Shanahan. There has been no recent trading activity by Mrs Shanahan but the updated notice now includes 80,000 shares held in a charitable foundation of which Mrs Shanahan is […]

Download PDF
 
Tuesday, 15 January 2019

CLINUVEL Newsletter – January 2019

15 January 2019   Dear patients, shareholders, friends, I wish you all a year in good physical and spiritual health, and a year in which we anticipate further progress of SCENESSE ® (afamelanotide 16mg)1 and CLINUVEL’s other products and activities. We look to a rather full year of events affecting CLINUVEL in one way or […]

Download PDF